Published in AIDS on June 01, 1989
Rectal gonorrhoea as an independent risk factor for HIV infection in a cohort of homosexual men. Genitourin Med (1995) 2.22
Use of dried blood spot specimens in the detection of human immunodeficiency virus type 1 by the polymerase chain reaction. J Clin Microbiol (1991) 2.05
Use of CD4 lymphocyte count to predict long-term survival free of AIDS after HIV infection. BMJ (1994) 1.87
Markers predicting progression of human immunodeficiency virus-related disease. Clin Microbiol Rev (1994) 1.19
Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS (1997) 9.08
Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA (2001) 7.63
Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA (1998) 6.69
Barriers to use of free antiretroviral therapy in injection drug users. JAMA (1998) 6.67
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA (1997) 6.35
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA (1996) 5.29
Unsafe injection practices in a cohort of injection drug users in Vancouver: could safer injecting rooms help? CMAJ (2001) 4.96
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA (1998) 4.61
HIV-1 and the aetiology of AIDS. Lancet (1993) 3.69
Prevalence and structural correlates of gender based violence among a prospective cohort of female sex workers. BMJ (2009) 3.56
Hospital utilization and costs in a cohort of injection drug users. CMAJ (2001) 3.48
Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ (1999) 3.35
Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study Group. AIDS (1989) 3.19
Decline in deaths from AIDS due to new antiretrovirals. Lancet (1997) 3.13
Do needle exchange programmes increase the spread of HIV among injection drug users?: an investigation of the Vancouver outbreak. AIDS (1999) 3.01
Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr (2000) 2.94
Impact of HIV infection on mortality in a cohort of injection drug users. J Acquir Immune Defic Syndr (2001) 2.80
Changes in sexual behaviour and fear of AIDS. Lancet (1984) 2.76
A reality check: the cost of making post-exposure prophylaxis available to gay and bisexual men at high sexual risk. AIDS (2000) 2.71
Patterns of sexual behavior and condom use in a cohort of homosexual men. Am J Public Health (1988) 2.57
Lower socioeconomic status and shorter survival following HIV infection. Lancet (1994) 2.47
Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ (2001) 2.47
Industry-sponsored clinical research: a double-edged sword. Lancet (2001) 2.45
HTLV-III infection in Canada in 1985. CMAJ (1986) 2.44
Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa. Lancet (2000) 2.42
Quantification of human immunodeficiency virus type 1 RNA from dried plasma spots collected on filter paper. J Clin Microbiol (1997) 2.37
The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs. Clin Infect Dis (1998) 2.31
Rectal gonorrhoea as an independent risk factor for HIV infection in a cohort of homosexual men. Genitourin Med (1995) 2.22
An anonymous seroprevalence survey of HIV infection among pregnant women in British Columbia and the Yukon Territory. CMAJ (1990) 2.21
Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS (2001) 2.15
The Vancouver Lymphadenopathy-AIDS Study: 4. Effects of exposure factors, cofactors and HTLV-III seropositivity on number of helper T cells. Can Med Assoc J (1985) 2.11
Decreasing frequency but worsening mortality of acute respiratory failure secondary to AIDS-related Pneumocystis carinii pneumonia. Chest (1994) 2.10
Stability of dried blood spot specimens for detection of human immunodeficiency virus DNA by polymerase chain reaction. J Clin Microbiol (1992) 2.10
Social determinants predict needle-sharing behaviour among injection drug users in Vancouver, Canada. Addiction (1997) 2.06
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS (2001) 2.03
The Vancouver Lymphadenopathy-AIDS Study: 6. HIV seroconversion in a cohort of homosexual men. CMAJ (1986) 2.01
Triple-combination antiretroviral therapy in sub-Saharan Africa. Lancet (1997) 2.00
Determinants of sexual risk-taking among young HIV-negative gay and bisexual men. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.99
Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS (1999) 1.87
Determinants of HIV seroconversion in injection drug users during a period of rising prevalence in Vancouver. Int J STD AIDS (1997) 1.85
Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS (1999) 1.85
Risky sexual behaviours among injection drugs users with high HIV prevalence: implications for STD control. Sex Transm Infect (2002) 1.81
Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS (1998) 1.81
Dietary factors and the incidence of cancer of the stomach. Am J Epidemiol (1985) 1.79
Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial. AIDS (1989) 1.78
Risk factors in pediatric AIDS. Can Med Assoc J (1985) 1.77
World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS (2001) 1.73
Surviving the sex trade: a comparison of HIV risk behaviours among street-involved women in two Canadian cities who inject drugs. AIDS Care (2003) 1.69
Quantification of the variation due to laboratory and physiologic sources in CD4 lymphocyte counts of clinically stable HIV-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.68
The social determinants of emergency department and hospital use by injection drug users in Canada. J Urban Health (1999) 1.67
HIV infection and risk behaviours among young gay and bisexual men in Vancouver. CMAJ (2000) 1.66
Chlamydia trachomatis infections in women with urogenital symptoms. Can Med Assoc J (1982) 1.63
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. J Infect Dis (2001) 1.62
The Vancouver Lymphadenopathy-AIDS Study: 3. Relation of HTLV-III seropositivity, immune status and lymphadenopathy. Can Med Assoc J (1985) 1.59
Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS (1995) 1.58
Evidence for a sexually transmitted cofactor for AIDS-related Kaposi's sarcoma in a cohort of homosexual men. Epidemiology (1992) 1.53
Antiretroviral medication use among injection drug users: two potential futures. AIDS (2000) 1.53
The Vancouver Lymphadenopathy-AIDS Study: 1. Persistent generalized lymphadenopathy. Can Med Assoc J (1985) 1.47
A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J Infect Dis (1995) 1.46
Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS (2001) 1.45
Depressive symptoms decline among persons on HIV protease inhibitors. J Acquir Immune Defic Syndr (2000) 1.42
Underreporting of AIDS cases in Canada: a record linkage study. CMAJ (1990) 1.39